More on IMMX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.13 |
|
|||
| Open | $2.14 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $2.35 | ||||
| Day Low | $2.08 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 79,995 | ||||
- Immix Biopharma on Track to Dose NXC-201 Patients in United States
- Immix Biopharma (IMMX) Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at ASGCT
- Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
- Form 10-K Immix Biopharma, Inc. For: Dec 31
- Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
- Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
- Immix Biopharma 12 Month Review Progress Update
- Form S-8 Immix Biopharma, Inc.
- Form 424B5 Immix Biopharma, Inc.
- Immix Biopharma (IMMX) Granted EU Orphan Drug Designation for NXC-201
Entities mentioned with IMMX
- FDA | View Related Stories »
- IPO | View Related Stories »
- ThinkEquity | View Related Stories »
- S1 | View Related Stories »
- 13G | View Related Stories »
- BofA/Merrill Lynch | View Related Stories »
- Equity Offerings | View Related Stories »
- JMP Securities | View Related Stories »
- Show More...
